IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients

NCT03203005 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: IMA970A plus CV8102 and Cyclophosphamide

Sponsor

National Cancer Institute, Naples

Collaborators

[object Object]
[object Object]
[object Object]